Retatrutide Side Effects UK — Complete Guide from Phase 2 Clinical Trials

Retatrutide Side Effects UK — What the Phase 2 Clinical Trial Data Shows

Understanding retatrutide side effects before you start is essential for safe and effective use. The good news: the side effect profile from Phase 2 trials is well-characterised, dose-dependent and largely manageable with proper titration. This guide covers every side effect reported in the NEJM Phase 2 trial, how common each is, and exactly what to do if you experience them.

The Most Common Retatrutide Side Effects (GI-Related)

Like all GLP-1 class peptides, the most common retatrutide side effects are gastrointestinal. They occur because GLP-1 receptors are present throughout the gut, and receptor activation slows gastric motility. The key facts:

• All GI side effects are dose-dependent — they increase with higher doses
• All GI side effects are typically transient — they reduce significantly after 4–6 weeks at a stable dose
• All GI side effects can be dramatically reduced with slow titration as per your physician protocol

Retatrutide Side Effects — Phase 2 Trial Frequency Data

Side Effect	Frequency (24mg dose)	Frequency (2mg dose)	Severity
Nausea	48%	18%	Mild–Moderate
Diarrhoea	32%	14%	Mild
Vomiting	22%	8%	Mild–Moderate
Constipation	21%	12%	Mild
Decreased appetite	16%	8%	Mild (desired effect)
Abdominal pain	12%	6%	Mild
Injection site reaction	8%	6%	Mild, local
Heart rate increase	9%	3%	Mild, transient
Fatigue	7%	4%	Mild

Source: Jastreboff AM et al., NEJM 2023

How to Manage Retatrutide Nausea

Nausea is the most common retatrutide side effect and the most frequently cited reason for dose reduction or discontinuation in the trial. Here’s how to manage it effectively:

• Eat smaller meals: Retatrutide slows gastric emptying — large meals sit in the stomach longer and cause nausea. Eat 50–60% of your normal portion size
• Avoid high-fat, high-calorie meals on injection day and the day after — these are most likely to trigger nausea
• Time your injection: Many users find injecting at bedtime minimises nausea by sleeping through the peak effect period
• Stay hydrated: Dehydration worsens nausea — drink 2–3 litres of water daily
• Don’t lie down immediately after eating: Stay upright for at least 2 hours after meals
• Slow your titration: If nausea persists beyond week 3 at a new dose, do not escalate — wait until nausea resolves before increasing

Heart Rate Increase — The Glucagon Effect

Retatrutide’s glucagon (GCG) receptor activation produces a modest heart rate increase not typically seen with semaglutide or tirzepatide. In the Phase 2 trial, mean heart rate increased by approximately 4–6 beats per minute. This is generally well-tolerated in healthy adults but warrants monitoring in patients with pre-existing cardiovascular conditions.

If you notice palpitations or a significant heart rate increase at higher retatrutide doses, contact your physician. Do not increase your dose until this has been evaluated.

Retatrutide Side Effects vs Semaglutide and Tirzepatide

Side Effect	Retatrutide	Tirzepatide	Semaglutide
Nausea (any grade)	48%	44%	44%
Diarrhoea	32%	30%	30%
Vomiting	22%	22%	24%
Heart rate increase	Yes (glucagon)	Mild	Mild
Fatigue	7%	8%	11%

The GI side effect profiles are broadly similar across the GLP-1 class. Retatrutide’s unique addition is the modest heart rate increase from glucagon receptor activation.

Rare but Serious Side Effects — When to Seek Help

While uncommon, the following require immediate medical attention:

• Severe abdominal pain radiating to the back (may indicate pancreatitis — discontinue immediately)
• Significant palpitations or chest discomfort persisting beyond 24 hours
• Severe allergic reaction — rash, swelling, difficulty breathing (anaphylaxis — extremely rare)
• Severe, persistent vomiting preventing fluid intake (dehydration risk)
• Symptoms of gallbladder disease — GLP-1 class peptides increase gallstone risk with rapid weight loss

Retatrutide and Thyroid Risk — What You Need to Know

GLP-1 receptor agonists caused thyroid C-cell tumours in rodent studies. The clinical significance in humans is unknown. Retatrutide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). If you have any thyroid history, consult your physician before starting retatrutide.

Ready to Start Retatrutide Safely?

Buy Synedica Retatrutide 40mg UK or Alluvi Retatrutide 40mg UK from £299/month — every order includes a physician-reviewed titration protocol designed to minimise side effects. Have questions? WhatsApp our team →

Related: Retatrutide dosage guide · How retatrutide works · Retatrutide results